866587-80-6

Basic information

• Product Name: 3-(1,3,5-trimethylpyrazol-4-yl)benzaldehyde
• Synonyms: 3-(1,3,5-trimethylpyrazol-4-yl)benzaldehyde
• CAS NO: 866587-80-6
• Molecular Weight: 214.267
• Mol File: 866587-80-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-(1,3,5-trimethylpyrazol-4-yl)benzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(1,3,5-trimethylpyrazol-4-yl)benzaldehyde(866587-80-6)
• EPA Substance Registry System: 3-(1,3,5-trimethylpyrazol-4-yl)benzaldehyde(866587-80-6)

Safety Data

• Hazardous Substances Data: 866587-80-6(Hazardous Substances Data)

Upstream product

• 1072-91-9 1,3,5-trimethyl-1H-pyrazole 
• 3132-99-8 m-bromobenzoic aldehyde 
• 15801-69-1 4-bromo-1,3,5-trimethylpyrazole 
• 87199-16-4 3-Formylphenylboronic acid 

Downstream Products

• 866587-81-7 [3-(1,3,5-trimethyl-1H-pyrazol-4-yl)phenyl]methanol 

Relevant articles and documents

Identification of highly potent and orally available free fatty acid receptor 1 agonists bearing isoxazole scaffold

The free fatty acid receptor 1 (FFA1) is being considered to be a novel anti-diabetic target based on its role in amplifying insulin secretion. We have previously identified several series of FFA1 agonists with different heterocyclic scaffolds. Herein, we describe the structural exploration of other heterocyclic scaffolds directed by drug-like physicochemical properties. Further structure-based design and chiral resolution provided the most potent compound 11 (EC50 = 7.9 nM), which exhibited improved lipophilicity (LogD7.4: 1.93), ligand efficiency (LE = 0.32) and ligand lipophilicity efficiency (LLE = 6.2). Moreover, compound 11 revealed an even better pharmacokinetic property than that of TAK-875 in terms of plasma clearance, maximum concentration, and plasma exposure. Although robust agonistic activity and PK profiles for compound 11, the glucose-lowering effects in vivo is not ideal, and the exact reason for in vitro/in vivo difference was worthy for further exploration.

ALKOXYPHENYLPROPANOIC ACID DERIVATIVES

The present invention aims at provision of a novel compound having a GPR40 receptor function modulating action, which is useful as an insulin secretagogue, an agent for the prophylaxis or treatment of diabetes and the like. The compound represented by the formula: wherein each symbol is as defined in the description, a salt thereof, and a prodrug thereof of the present invention unexpectedly have a superior GPR40 receptor agonistic activity and superior properties as pharmaceutical products such as stability and the like, and can be safe and useful pharmaceutical agents as agents for the prophylaxis or treatment of GPR40 receptor-related pathology or diseases in mammals.